What's the most recent regulatory action in Osteomyelitis due to Staphylococcus aureus?

Most recent: Cleocin T — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/osteomyelitis-due-to-staphylococcus-aureus.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Osteomyelitis due to Staphylococcus aureus — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Osteomyelitis due to Staphylococcus aureus (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Osteomyelitis due to Staphylococcus aureus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Augmentin 250	CLAVULANIC ACID	Dr Reddys Labs Inc	beta Lactamase Inhibitor		1984-01-01
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Cefaprin	cefapirin	Bristol-Myers Squibb	cefapirin	Sigma non-opioid intracellular receptor 1	1974-01-01
Cleocin T	CLINDAMYCIN PHOSPHATE	Pfizer	Lincosamide Antibacterial		1972-01-01
Keflex	cefalexin	Shionogi	Cephalosporin Antibacterial	Solute carrier family 15 member 2	1971-01-01
Bactocill In Plastic Container	OXACILLIN	Apothecon		Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1971-01-01
Cleocin	clindamycin	Generic (originally Upjohn/Pfizer)	Lincosamide antibiotic	50S ribosomal protein L10	1970-01-01
Nallpen In Plastic Container	NAFCILLIN	Pfizer	Penicillin-class Antibacterial		1965-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-23 — Cleocin T · FDA · approved · US
2026-03-18 — Cleocin T · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 8 drugs in Osteomyelitis due to Staphylococcus aureus
Pfizer · 4 drugs in Osteomyelitis due to Staphylococcus aureus
Pai Holdings Pharm · 2 drugs in Osteomyelitis due to Staphylococcus aureus
Bristol-Myers Squibb · 1 drug in Osteomyelitis due to Staphylococcus aureus
Dr Reddys Labs Inc · 1 drug in Osteomyelitis due to Staphylococcus aureus
GSK · 1 drug in Osteomyelitis due to Staphylococcus aureus
Generic (originally Upjohn/Pfizer) · 1 drug in Osteomyelitis due to Staphylococcus aureus
Novartis · 1 drug in Osteomyelitis due to Staphylococcus aureus
Shionogi · 1 drug in Osteomyelitis due to Staphylococcus aureus
Tel-Aviv Sourasky Medical Center · 1 drug in Osteomyelitis due to Staphylococcus aureus
University Hospital, Lille · 1 drug in Osteomyelitis due to Staphylococcus aureus
ANI Pharmaceuticals · 1 drug in Osteomyelitis due to Staphylococcus aureus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Osteomyelitis due to Staphylococcus aureus:

Cite this brief

Drug Landscape (2026). Osteomyelitis due to Staphylococcus aureus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/osteomyelitis-due-to-staphylococcus-aureus. Accessed 2026-06-10.

Osteomyelitis due to Staphylococcus aureus full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing